Board Meeting Details

The Board Meeting commenced at 2:30 PM and concluded at 6:30 PM on November 13, 2026.

Key Decisions Approved

1. Financial Results Approval: Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter and Half Year ended September 30, 2026.

2. Preferential Allotment of Securities: Approved the allotment of securities on a preferential basis pursuant to:

  • Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
  • In-principle approvals received from BSE Limited and National Stock Exchange of India Limited on November 04, 2026
  • Special resolution passed by shareholders at the Extra-Ordinary General Meeting held on September 09, 2026

Preferential Allotment Details

Equity Shares Allotment:

  • 1,12,500 fully paid-up Equity Shares of face value ₹10/- each
  • Issue price: ₹178.00 per share (including a premium of ₹168.00 per share)
  • Total aggregate value: ₹2,00,25,000/- (Rupees Two Crores Twenty-Five Thousand Only)
  • Allottee: Mr. Sunil L Mundra (Promoter Individual)

Convertible Warrants Allotment:

  • 4,50,000 Fully Convertible Warrants
  • Issue price: ₹178.00 per warrant
  • Each warrant carries an option to subscribe to 1 (one) fully paid-up Equity Share of face value ₹10/- each
  • 25% upfront subscription money: ₹44.50 per warrant (₹2,00,25,000/- total)
  • Total warrant value: ₹8,01,00,000/- (Rupees Eight Crores One Lakh Only)
  • Allottee: Mr. Sunil L Mundra (Promoter Individual)

Warrant Conversion Terms

  • Each warrant convertible into one equity share within 18 (Eighteen) months from date of allotment
  • 25% of Warrant Exercise Price payable at time of subscription and allotment
  • Balance 75% payable at time of allotment of Equity Shares upon exercise of options
  • Amount paid against warrants adjustable against issue price for resultant Equity Shares
  • If warrant not exercised within 18 months, warrant lapses and 25% upfront payment forfeited

Post-Allotment Shareholding Impact

Pre-Preferential Allotment (as of November 13, 2026):

  • Mr. Sunil L Mundra: 6,02,290 shares (5.79% holding)

Post-Preferential Allotment (assuming full warrant conversion):

  • Mr. Sunil L Mundra: 11,64,790 shares (10.61% holding)
  • Increase of 5,62,500 shares (4.82% increase)

Financial Results Highlights

Standalone Financials (Quarter Ended September 30, 2026):

  • Revenue from operations: ₹4,748.09 lakhs
  • Other Income: ₹236.50 lakhs
  • Total Income: ₹4,984.59 lakhs
  • Total Expenses: ₹4,351.07 lakhs
  • Profit before tax: ₹633.52 lakhs
  • Tax Expense: ₹145.10 lakhs (Current Tax: ₹161.53 lakhs, Deferred Tax: ₹-16.43 lakhs)
  • Net Profit after tax: ₹488.42 lakhs
  • Earnings Per Share (Basic & Diluted): ₹4.71
  • Paid-Up Equity Share Capital: ₹1,041.12 lakhs (face value ₹10/- per share)

Standalone Financials (Half Year Ended September 30, 2026):

  • Revenue from operations: ₹9,050.16 lakhs
  • Other Income: ₹467.34 lakhs
  • Total Income: ₹9,517.50 lakhs
  • Total Expenses: ₹8,317.74 lakhs
  • Profit before tax: ₹1,199.76 lakhs
  • Tax Expense: ₹307.71 lakhs
  • Net Profit after tax: ₹892.05 lakhs
  • Earnings Per Share (Basic & Diluted): ₹8.59

Consolidated Financials (Quarter Ended September 30, 2026):

  • Revenue from operations: ₹5,115.28 lakhs
  • Other Income: ₹16.66 lakhs
  • Total Income: ₹5,131.94 lakhs
  • Total Expenses: ₹5,592.33 lakhs
  • Loss before tax: ₹-460.39 lakhs
  • Tax Expense: ₹35.91 lakhs
  • Net Loss after tax: ₹-496.30 lakhs
  • Net Loss attributable to shareholders: ₹-712.70 lakhs
  • Earnings Per Share (Basic & Diluted): ₹-6.84

Consolidated Financials (Half Year Ended September 30, 2026):

  • Revenue from operations: ₹9,986.47 lakhs
  • Other Income: ₹35.38 lakhs
  • Total Income: ₹10,021.85 lakhs
  • Total Expenses: ₹11,063.47 lakhs
  • Loss before tax: ₹-1,041.62 lakhs
  • Tax Expense: ₹44.52 lakhs
  • Net Loss after tax: ₹-1,086.14 lakhs
  • Net Loss attributable to shareholders: ₹-1,506.12 lakhs
  • Earnings Per Share (Basic & Diluted): ₹-14.45

Subsidiary Information

Consolidated results include:

  • Natural Phyto Pharma Private Limited (Subsidiary)
  • Natural Biogenex Private Limited (Subsidiary)

One subsidiary with immaterial impact included in consolidation:

  • Total assets: ₹2.96 lakhs
  • Total revenues: Nil for half year ended September 30, 2026
  • Net profit after tax: Nil for half year ended September 30, 2026

Investor Complaints

For quarter ended September 30, 2026:

  • Pending as on July 1, 2026: Nil
  • Received during quarter: 1
  • Resolved during quarter: 1
  • Pending as on September 30, 2026: Nil

Additional Information

  • The allotted shares shall rank pari-passu with existing equity shares
  • Application for listing approval to stock exchanges will be made in due course
  • No cancellation or termination of the securities issuance proposal